Navigation Links
IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting

IRVINE, Calif., May 16 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that clinical data presentations evaluating the Company's lead product candidates will be made at the upcoming 44th American Society of Clinical Oncology (ASCO) annual meeting. Data presented at the meeting will support improved survival for patients with metastatic osteosarcoma treated with L-MTP-PE, as well as patients with non-small lung cancer treated with IDM-2101.

Presentation highlights are as follows:


"Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly

Diagnosed Metastatic Osteosarcoma: a Report from the Children's Oncology


Presenter: Alexander J Chou, MD, Department of Pediatrics, Memorial

Sloan-Kettering Cancer Center

Date/Time: Poster presentation, Sunday, June 1, 2008, 2 - 6 p.m., S Hall

A1; poster discussion period, 4:45 - 6 p.m., S504

Abstract Number: 10018

Poster Number: 52B


"Induction of immune responses and clinical activity in a Phase 2 trial of

IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients"

Presenter: Minal Barve, MD, practice director, Mary Crowley Cancer

Research Center

Date/Time: Sunday, June 1, 2008, 2 - 6 p.m., S Hall A1

Abstract Number: 8057

Poster Number: 43D

The 2008 ASCO annual meeting abstracts are currently available at

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit

Forward-Looking Statements

The presentations described in this press release will include forward- looking statements that reflect management's current views of future events regarding the development and characteristics of the Company's drug candidates L-MTP-PE and IDM-2101, including the Company's plans to address the remaining questions with respect to the Marketing Authorization Application (MAA) for L- MTP-PE during the clock-stop granted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended New Drug Application (NDA) for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the Food and Drug Administration (FDA), the potential for IDM-2101 as a treatment for NSCLC and plans to evaluate strategic alternatives. Actual results may differ materially from the forward- looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to respond to the remaining issues with regard to the MAA, including verification of data quality and chemistry, manufacturing and controls (CMC) items, to the satisfaction of the CHMP, whether the CHMP will ask the Company for further information at or following the June 2008 meeting to address remaining issues with regard to the MAA, which would delay the timing of a final opinion from the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP- PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP- PE even if it is approved by regulatory authorities, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jazz Pharmaceuticals to Present at Investor Conferences
2. Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
3. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
4. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
5. Wyeths Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
6. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
7. 11 Pharmaceutical Titans Headline Chemistry Outsourcing Conference Program in September in New Jersey
8. AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
9. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
10. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
11. Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: